64Cu-DOTA-Rituximab PET/CT of B-Cell Non-Hodgkin Lymphoma for Imaging the CD20 Expression

被引：5
|
作者：
Lee, Inki [1 ]
Lim, Ilhan [1 ,2 ,3 ,6 ]
Lee, Kyo Chul [2 ]
Kang, Hye Jin [4 ,5 ]
Lim, Sang Moo [1 ]
机构：
[1] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Nucl Med, Seoul, South Korea
[2] Korea Inst Radiol & Med Sci, Res Inst Radiol & Med Sci, Div Appl RI, Seoul, South Korea
[3] Univ Sci & Technol, Dept Radiol & Med Oncol Sci, Seoul, South Korea
[4] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea
[5] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Internal Med, Div Hematol Oncol, 75,Nowon Ro, Seoul, South Korea
[6] Korea Canc Ctr Hosp, Korea Inst Radiol & Med Sci, Dept Nucl Med, 75,Nowon Ro, Seoul, South Korea
来源：
CLINICAL NUCLEAR MEDICINE | 2023年 / 48卷 / 02期
基金：
新加坡国家研究基金会;
关键词：
Cu-64-DOTA-rituximab; B-cell lymphoma; CD20; antigen; positron emission tomography; POSITRON-EMISSION-TOMOGRAPHY; FDG-PET;
D O I：
10.1097/RLU.0000000000004378
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Cu-64-DOTA-rituximab PET/CT was performed on a 62-year-old and a 71-year-old men diagnosed with B-cell non-Hodgkin lymphoma. Compared with F-18-FDG PET/CT, lesions could be detected more sensitively, and it was confirmed that there was no discernible Cu-64-DOTA-rituximab uptake in the tumor other than lymphoma. Cu-64-DOTA-rituximab PET/CT could be a powerful tool for the diagnosis and monitoring treatment response of lymphoma because of imaging the CD20 expression.
引用
收藏
页码：E82 / E83
页数：2
相关论文
共 50 条
  • [21] Evaluating 64Cu-DOTA-rituximab as a PET agent in patients with B-cell lymphoma: a head-to-head comparison with 18F-fluorodeoxyglucose PET/computed tomography
    Lee, Inki
    Byun, Byung Hyun
    Kim, Byung Il
    Choi, Chang Woon
    Kang, Hye Jin
    Kang, Chi Soo
    Woo, Sang-Keun
    Lee, Kyo Chul
    Kang, Joo Hyun
    Lim, Ilhan
    NUCLEAR MEDICINE COMMUNICATIONS, 2024, 45 (10) : 865 - 873
  • [22] Incidence and nature of CD20 negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: A retrospective review.
    Kennedy, GA
    Tey, SK
    Cobcroft, R
    Marlton, P
    Grimmett, K
    Gill, D
    BLOOD, 2002, 100 (11) : 360A - 360A
  • [23] Restoration of rituximab sensitivity in CD20 negative B-Cell lymphoma, cells; Epigenetic change of CD20 expression after treatment of rituximab.
    Tomita, Akihiro
    Hiraga, Junji
    Kiyoi, Hitoshi
    Kinoshita, Tomohiro
    Naoe, Tornoki
    BLOOD, 2006, 108 (11) : 155B - 155B
  • [24] Aberrant Expression of CD8 in B-Cell Non-Hodgkin Lymphoma
    Carulli, Giovanni
    Stacchini, Alessandra
    Marini, Alessandra
    Ciriello, Maria Matilde
    Zucca, Alessandra
    Cannizzo, Elisa
    Aliberti, Sabrina
    Demurtas, Anna
    Novero, Domenico
    Calcagno, Lara
    Callegari, Tiziana
    Petrini, Mario
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 132 (02) : 186 - 190
  • [25] Rituximab maintenance therapy in CD20+B-cell non-Hodgkin's lymphoma
    Trajkova, SA
    Cevreska, LA
    Panovska-Stavridis, IZ
    Pivkova, A
    Georgievski, B
    Karanfilski, OB
    Stojanovic, AT
    Wenger, MK
    BLOOD, 2005, 106 (11) : 282B - 282B
  • [26] Efficacy and tolerability of rituximab-based chemotherapy in CD20 positive non-Hodgkin lymphoma
    Cedrych, I.
    Polakiewicz-Gilowska, A.
    Nowara, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 246 - 246
  • [27] Maintenance therapy using the anti-CD20 antibody Rituximab in patients with B-cell non-Hodgkin lymphoma
    Neumann, F
    Martin, S
    Kronenwett, R
    Fischer, C
    Kondakci, M
    Kobbe, G
    Gattermann, N
    Haas, R
    BLOOD, 2003, 102 (11) : 298B - 298B
  • [28] Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas
    Perez-Callejo, D.
    Gonzalez-Rincon, J.
    Sanchez, A.
    Provencio, M.
    Sanchez-Beato, M.
    CANCER TREATMENT REVIEWS, 2015, 41 (08) : 680 - 689
  • [29] CD20-Specific Chimeric Antigen Receptor- Expressing T Cells As Salvage Therapy in Rituximab-Refractory CD20(+) B-Cell Non-Hodgkin Lymphoma
    Li, Xin
    Cheng, Qian
    Liu, Rui
    Kang, Liqing
    Xu, Nan
    Li, Minghao
    Yu, Lei
    BLOOD, 2021, 138
  • [30] Use of C-terminal deletion mutation of CD20 molecule to predict CD20 expression and time to progression after rituximab in non-Hodgkin lymphoma
    Terui, Y.
    Mishima, Y.
    Yokoyama, M.
    Mishima, Y.
    Takeuchi, K.
    Ito, Y.
    Takahashi, S.
    Hatake, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345